Miodrag Radulovacki

Miodrag Radulovacki

Auto-generated profile, based on publicly available information

Miodrag Radulovacki

Department of Pharmacology, University of Illinois at Chicago, 60612, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Frontiers in Psychiatry
Verified
Journal Article
Open access
Bharati PrasadBharati Prasad
Bharati Prasad
MRMiodrag G. Radulovacki
Miodrag G. Radulovacki
DCDavid W. Carley
David W. Carley
Study Objective: Animal data suggest that Δ9-TetraHydroCannabinol (Δ9THC) stabilizes autonomic output during sleep, reduces spontaneous sleep-disordered breathing, and blocks serotonin-induced exacerbation of sleep apnea. On this basis, we examined the safety, tolerability, and efficacy of dronabinol (Δ9THC), an exogenous Cannabinoid type 1 and type 2 (CB1 and CB2) receptor agonist in patients with Obstructive Sleep Apnea (OSA). Design and Setting: Proof of concept; single-center dose-escalation study of dronabinol. Participants: Seventeen adults with a baseline Apnea Hypopnea Index (AHI) ≥15/h. Baseline polysomnography (PSG) was performed after a 7-day washout of Continuous Positive Airway Pressure treatment. Intervention: Dronabinol was administered after baseline PSG, starting at 2.5 mg once daily. The dose was increased weekly, as tolerated, to 5 mg and finally to 10 mg once daily. Measurements and Results: Repeat PSG assessments were performed on nights 7, 14, and 21 of dronabinol treatment. Change in AHI (ΔAHI, mean ± SD) was significant from baseline to night 21 (−14.1 ± 17.5; p = 0.007). No degradation of sleep architecture or serious adverse events was noted. Conclusion: Dronabinol treatment is safe and well-tolerated in OSA patients at doses of 2.5–10 mg daily and significantly reduces AHI in the short-term. These findings should be confirmed in a larger study in order to identify sub-populations with OSA that may benefit from cannabimimetic pharmacologic therapy.

1 March 2005 in Neurological Research
Verified
Journal Article
Closed access
MRMiodrag Radulovacki
Miodrag Radulovacki

1 May 2004 in SLEEP
Verified
Journal Article
Open access
PDF file
MRMiodrag Radulovacki
Miodrag Radulovacki
SPSasa Pavlovic
Sasa Pavlovic
DCDavid W. Carley
David W. Carley
Study Objectives:To determine whether the pontine intertrigeminal region (ITR), with recently described anatomic connections and an effect on vagally induced reflex apnea, has an impact on spontaneous sleep apneas in rats.Design:Respiration, electroencephalogram (EEG), and electromyogram (EMG) were recorded in rats with lesions of the pontine ITR and in control animals.Participants:9 adult male Sprague-Dawley rats.Interventions:Rats were implanted with EEG and EMG electrodes and were polygraphically recorded for 6 hours, and their respiration was monitored by placing each animal inside a single-chamber plethysmograph. Subsequently, a respiratory-related intertrigeminal site was identified by probing on dorsoventral tracks with 2 to 5 nL glutamate (10 nL, 10 mmol) injections from a multibarrel glass pipette. This site was then lesioned by injecting ibotenic acid (10 nL, 50 mmol) from a second pipette barrel. Animals were again recorded for 6 hours on days 2, 7, and 14 after the lesion.Measurements and Results:ITR lesions exerted no impact on mean respiratory pattern during any sleep-wake state, compared to baseline recordings. In contrast, apnea frequency during non-rapid eye movement sleep increased following ITR lesion, more than doubling by day 14.Conclusions:This study demonstrates that a small and well-localized unilateral lesion of the ITR region in the lateral pons can increase sleep apnea expression in freely moving rats over a 2-week period. The present findings are in agreement with the general modulatory role of pontine structures in activities including respiration, heart rate, and regulation of blood pressure.

1 November 2001 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Closed access
PDF file
MRMiodrag Radulovacki
Miodrag Radulovacki
SPSasa Pavlovic
Sasa Pavlovic
ARAndrei Rakic
Andrei Rakic
MJMarika Janelidze
Marika Janelidze
LSLisa Shermulis
Lisa Shermulis
DCDavid W. Carley
David W. Carley
We conducted this experiment to determine the role of glutamate in the mechanism of sleep apnoeas by administering riluzole, a glutamate release inhibitor, to freely moving rats in which sleep-related apnoeas are physiological phenomena. Adult Sprague-Dawley rats were implanted with electrodes for electroencephalogram (EEG) and electromyogram (EMG) recording to monitor sleep and were placed inside a single-chamber plethysmograph to monitor respiration. Sleep and respiration were recorded for 6 h following intraperitoneal administration of 0.5, 5.0 and 10.0 mg kg−1 riluzole. Riluzole dose-dependently suppressed post-sigh apnoeas during rapid eye movement (REM) sleep but had no effect on sleep-related spontaneous apnoeas. The drug (5.0 and 10.0 mg kg−1) also dose-dependently reduced wakefulness and increased sleep. It appears that glutamate, an excitatory neurotransmitter, plays a role in the genesis of the post-sigh apnoeas during REM sleep.

1 April 2007 in Respiratory Physiology & Neurobiology
Verified
Journal Article
Closed access
MRMiodrag Radulovacki
Miodrag Radulovacki
MSMilan Stoiljkovic
Milan Stoiljkovic
JSJasna Saponjic
Jasna Saponjic
DCDavid W. Carley
David W. Carley

6 February 2010 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
SKSrdjan Kesic
Srdjan Kesic
AKAleksandar Kalauzi
Aleksandar Kalauzi
MRMiodrag Radulovacki
Miodrag Radulovacki
DCDavid W. Carley
David W. Carley
JSJasna Saponjic
Jasna Saponjic